Holen Sie sich die Stockscreener-App
15.20
3.92%
-0.62
Schlusskurs vom Vortag:
$15.82
Offen:
$16.03
24-Stunden-Volumen:
2.51M
Relative Volume:
0.93
Marktkapitalisierung:
$2.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-451.71M
KGV:
-4.7116
EPS:
-3.2261
Netto-Cashflow:
$-462.19M
1W Leistung:
-5.18%
1M Leistung:
-39.54%
6M Leistung:
-19.32%
1J Leistung:
+21.12%
1-Tages-Spanne:
$15.09
$16.03
1-Wochen-Bereich:
$15.09
$16.80
52-Wochen-Spanne:
$12.43
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
15.20 | 2.99B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
(DYN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Dyne Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
DYN Maintained by Chardan Capital -- Price Target Holds at $38 - GuruFocus
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating By Investing.com - Investing.com Canada
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions By Investing.com - Investing.com Canada
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target - TradingView
DYN Maintained by HC Wainwright & Co. -- Price Target Lowered to $32 - GuruFocus
Jefferies reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data? - Simply Wall Street
Dyne Therapeutics stock rises on positive DM1 trial results - uk.finance.yahoo.com
After a year, Dyne trial participants showed better walking-test times and muscle strength - Stock Titan
DYN Reiterated by Piper Sandler -- Price Target Maintained at $4 - GuruFocus
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence - Investing.com Canada
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
TLX Stock Price and Chart — NASDAQ:TLX - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Yahoo Finance
What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders - simplywall.st
DYN: Strong clinical progress and launch readiness position the company for leadership in neuromuscular disease therapies - TradingView
Dyne Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN) - The Globe and Mail
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI
Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - Kalkine Media
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS) - theglobeandmail.com
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - stocktitan.net
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):